Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telitacicept in Pediatric IgA Nephropathy or IgA Vasculitis Nephritis
NCT07052981Phase 3Not yet recruiting
- Start
- Aug 2025
- Primary completion
- Jun 2027
- Modality
- Fc-Fusion Proteins
01
Overview
A Phase 3 trial of telitacicept in IgA nephropathy (IgAN), IgA vasculitis nephritis. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
telitacicept
03
Conditions
IgA nephropathy (IgAN)IgA vasculitis nephritis
Beyond the preview
Go deeper on NCT07052981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07052981.